A Phase II, Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Autologous Dendritic Cell Vaccination (ADCV01) as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADCV 01 (Primary) ; Temozolomide
Indications Glioblastoma
Focus Therapeutic Use
Sponsors Ever Supreme Bio Technology

Most Recent Events

13 Sep 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2026.
13 Sep 2024 Planned primary completion date changed from 31 Dec 2022 to 30 Dec 2026.
21 Mar 2022 Planned End Date changed from 30 Jun 2022 to 30 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight